Related Experiment Video
Updated: Sep 3, 2026

E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Attitudes of general practitioners to their interactions with pharmaceutical companies: a qualitative study
Objectives:
To obtain the attitudes of a sample of General Practitioners to their interactions with pharmaceutical companies.
Design:
Semi-structured face to face interviews.
Setting:
General Practices in the north-west of Ireland.
Results:
General Practitioners do not value their interactions with pharmaceutical representatives. They regard it as promotional, not educational activity and believe they are presented with biased information. Positive aspects (social, and receiving information) do not compensate. The content of educational meetings should be decided by G.Ps. alone. More directly promotional meetings are valued less, except when fairly lavish, in which case they are harder to resist. Material received through the post is not valued at all by G.Ps.
Conclusions:
Pharmaceutical companies in Ireland have a good relationship with G.Ps. It is in jeopardy. To rescue it, companies need to provide G.Ps. with assistance (information and other types) which is directly helpful to G.Ps. caring for their patients. Companies need to row back on the deluge of promotional material that G.Ps. are faced with. G.Ps. need to be trained to learn how to demand more helpful material from companies, and to refuse the promotional tidal wave.
Related Concept Videos
The Placebo Effect
Obedience
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Quantitative Aspects of Drug-Receptor Interaction
Bioavailability Study Design: Healthy Subjects Versus Patients
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence